XML 20 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities:    
Net loss available to common stockholders $ (10,375) $ (13,206)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 172 175
Reduction in the carrying amount of right-of-use assets 173 76
Change in fair value of warrants and SEPA liabilities 758 (2,521)
Change in fair value of OrbiMed Warrants and revenue base redemption liabilities 77 0
Change in fair value of contingent earnout liability 820 3,988
Non-cash interest expense 266 0
Stock-based compensation expense 1,620 1,086
Amount charged (recovered) to costs and expenses 39 0
Loss on disposal of property and equipment 117 18
Amortization of debt issuance costs 235 0
Changes in operating assets and liabilities:    
Accounts receivable (366) (723)
Inventory, net (114) (368)
Prepaid expenses 511 955
Deposits 0 43
Operating lease liabilities (56) (85)
Trade payables and accrued liabilities 1,624 (305)
Net cash used in operating activities (4,499) (10,867)
Cash flows from investing activities:    
Purchases of property and equipment (754) (66)
Proceeds from the disposal of property and equipment 40 0
Net cash used in investing activities (714) (66)
Cash flows from financing activities:    
Proceeds from the issuance of common stock 0 3,141
Debt issuance costs (520) 0
Proceeds from the issuance of debt 10,000 0
Payments on finance lease liabilities (71) (22)
Proceeds from the exercise of stock options for common stock 279 7
Net cash provided by financing activities 9,688 3,126
Increase (decrease) in cash, cash equivalents and restricted cash 4,475 (7,807)
Cash, cash equivalents and restricted cash, beginning of period 8,875 12,127
Cash, cash equivalents and restricted cash, end of period 13,350 4,320
Supplemental disclosures of cash flow information:    
Interest paid 709 3
Income taxes 1 0
Supplemental disclosures of non-cash items:    
Right-of-use assets obtained in exchange for new operating lease liabilities 0 90
Fixed asset purchase through exchange of finance lease right-of-use asset 85 0
Derecognition of finance lease right-of-use asset (85) 0
Fixed asset purchases included in trade payables and accrued expenses 87 0
Fair value of warrants issued related to OrbiMed debt 366 0
Non-cash interest expense $ 266 $ 0